A GENETIC RISK PROFILE IN LONGITUDINAL SYSTEMIC LUPUS ERYTHEMATOSES COHORTS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with autoimmune disease may have certain proteins in their circulation which may be an important factor in the development of disease. These proteins can interact with white blood cells and this interaction may cause damage to multiple tissues and organs. There is some evidence that inherited factors (genes) may contribute to the development of autoimmune disease. The three aims of the research study are: 1) Establish a multi-center common core database of systemic lupus erythematosus (SLE) patients from multiple ethnicities (profile cohorts) comprised of established patients who are already in local cohorts as well as new patients to be recruited; 2) Assess the ability of chromosome 1 genes (q21-32) to predict disease phenotype [renal, cardiovascular, pulmonary, and central nervous system (CNS) involvement] in this profile cohort of SLE patients; and 3) Establish a core set of trio families (lupus patients and both biological parents) and healthy controls to confirm and narrow the identification of candidate regions and genes in SLE. The first two goals will be accomplished through a longitudinal study of 700 SLE patients. The third goal will be accomplished through a study on 350 trio families (lupus patients and both biological patients). There will be an additional cohort (called CASSLE) which will include 800 lupus patients with any disease duration, as well as 800 controls. Each control will be matched to a case by race, age, and gender. The procedures will be the same as in the PROFILE cohort, except that the participants will only have one study visit. These aims will serve to create the largest number of lupus patients in whom meticulously gathered data will be available to study the genetics of lupus and the relative contributions of genetics (versus other factors) to disease phenotype. The Chicago cohort aims to provide 300 PROFILE/CASSLE patients and 50 TRIO families as well as 200 matched Controls for lupus patients.